✦ LIBER ✦

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

✍ Scribed by Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston

Book ID: 118001315
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 334 KB
Volume: 380
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)61769-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab for patients with relapsing

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

✍ Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Co 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 326 KB

Simvastatin as add-on therapy to interfe

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

✍ Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen W 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 349 KB

NORdic trial of oral Methylprednisolone

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial

✍ Per Soelberg Sorensen; Svein Ivar Mellgren; Anders Svenningsson; Irina Elovaara; 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 175 KB

Methylprednisolone in combination with i

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

✍ Mads Ravnborg; Per Soelberg Sørensen; Magnus Andersson; Elisabeth G Celius; Pete 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 374 KB

Efficacy of vitamin D3 as add-on therapy

Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial

✍ Joost Smolders; Raymond Hupperts; Frederik Barkhof; Luigi M.E. Grimaldi; Trygve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 355 KB

Comparison of two dosing frequencies of

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

✍ Giancarlo Comi; Nicola De Stefano; Mark S Freedman; Frederik Barkhof; Chris H Po 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 224 KB